Pancreatic Cancer Research

ResearcherQueen's UniversityActive in the last 2 years

James Biagi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2095-3592; OpenAlex author ID A5009452194. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 4 papers · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 4 papers

Papers 16

  1. Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG … Co-author DOI 10.1097/sla.0000000000006449↗
  2. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  3. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  4. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  5. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  6. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  7. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based … Co-author DOI 10.1016/j.clon.2023.02.008↗
  8. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  9. Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline. Co-author DOI 10.3390/curroncol30070482↗
  10. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  11. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  12. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  13. Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of t… Co-author DOI 10.3390/cancers14163945↗
  14. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Co-author DOI 10.1002/cam4.2705↗
  15. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3724↗
  16. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thierry Conroy · 8 shared papers, 2018–2026 · strength 1.45
  2. Jerome F. Cros · 6 shared papers, 2024–2026 · strength 1.23
  3. Aurélien Lambert · 6 shared papers, 2022–2026 · strength 1.19
  4. Pascal R. Hammel · 6 shared papers, 2018–2026 · strength 1.00
  5. Rémy Nicolle · 5 shared papers, 2024–2026 · strength 0.95
  6. Alexandre Harlé · 4 shared papers, 2024–2026 · strength 0.83
  7. Jean‐Baptiste Bachet · 5 shared papers, 2018–2026 · strength 0.80
  8. Anthony Turpin · 4 shared papers, 2024–2026 · strength 0.74
  9. Daniel John Renouf · 4 shared papers, 2024–2026 · strength 0.74
  10. Nelson Dusetti · 4 shared papers, 2024–2026 · strength 0.74
  11. Robert C. Grant · 5 shared papers, 2020–2026 · strength 0.64
  12. Jennifer Jane Knox · 5 shared papers, 2020–2026 · strength 0.64
  13. Steve Gallinger · 5 shared papers, 2020–2026 · strength 0.64
  14. Faiyaz Notta · 5 shared papers, 2020–2026 · strength 0.64
  15. Juan Iovanna · 3 shared papers, 2024–2026 · strength 0.55
  16. Emmanuel Mitry · 3 shared papers, 2024–2026 · strength 0.51
  17. Vinciane Rebours · 3 shared papers, 2024–2026 · strength 0.51
  18. Sandra Elisabeth Fischer · 4 shared papers, 2020–2023 · strength 0.43
  19. Yifan Wang · 4 shared papers, 2020–2023 · strength 0.43
  20. Grainne Mary O'Kane · 4 shared papers, 2020–2023 · strength 0.43
  21. George Zogopoulos · 4 shared papers, 2020–2023 · strength 0.43
  22. Alice Chia-Chi Wei · 3 shared papers, 2018–2026 · strength 0.41
  23. Nicolas Alejandro Fraunhoffer · 2 shared papers, 2024–2026 · strength 0.35
  24. Rama Khokha · 3 shared papers, 2020–2023 · strength 0.32
  25. Barbara T. Grünwald · 3 shared papers, 2020–2023 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.